128 related articles for article (PubMed ID: 11298761)
1. P-Glycoprotein conformational changes detected by antibody competition.
Nagy H; Goda K; Arceci R; Cianfriglia M; Mechetner E; Szabó G
Eur J Biochem; 2001 Apr; 268(8):2416-20. PubMed ID: 11298761
[TBL] [Abstract][Full Text] [Related]
2. Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells.
Goda K; Nagy H; Mechetner E; Cianfriglia M; Szabó G
Eur J Biochem; 2002 Jun; 269(11):2672-7. PubMed ID: 12047375
[TBL] [Abstract][Full Text] [Related]
3. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Nagy H; Goda K; Fenyvesi F; Bacsó Z; Szilasi M; Kappelmayer J; Lustyik G; Cianfriglia M; Szabó G
Biochem Biophys Res Commun; 2004 Mar; 315(4):942-9. PubMed ID: 14985103
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation.
Druley TE; Stein WD; Ruth A; Roninson IB
Biochemistry; 2001 Apr; 40(14):4323-31. PubMed ID: 11284688
[TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol-dependent conformational changes of P-glycoprotein are detected by the 15D3 monoclonal antibody.
Gutay-Tóth Z; Fenyvesi F; Bársony O; Szente L; Goda K; Szabó G; Bacsó Z
Biochim Biophys Acta; 2016 Mar; 1861(3):188-95. PubMed ID: 26704667
[TBL] [Abstract][Full Text] [Related]
7. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity.
Druley TE; Stein WD; Roninson IB
Biochemistry; 2001 Apr; 40(14):4312-22. PubMed ID: 11284687
[TBL] [Abstract][Full Text] [Related]
8. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Ruth A; Stein WD; Rose E; Roninson IB
Biochemistry; 2001 Apr; 40(14):4332-9. PubMed ID: 11284689
[TBL] [Abstract][Full Text] [Related]
9. The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.
Szalóki G; Krasznai ZT; Tóth Á; Vízkeleti L; Szöllősi AG; Trencsényi G; Lajtos I; Juhász I; Krasznai Z; Márián T; Balázs M; Szabó G; Goda K
PLoS One; 2014; 9(9):e107875. PubMed ID: 25238617
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.
Mechetner EB; Schott B; Morse BS; Stein WD; Druley T; Davis KA; Tsuruo T; Roninson IB
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):12908-13. PubMed ID: 9371774
[TBL] [Abstract][Full Text] [Related]
11. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.
Goda K; Fenyvesi F; Bacsó Z; Nagy H; Márián T; Megyeri A; Krasznai Z; Juhász I; Vecsernyés M; Szabó G
J Pharmacol Exp Ther; 2007 Jan; 320(1):81-8. PubMed ID: 17050779
[TBL] [Abstract][Full Text] [Related]
12. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.
Shepard RL; Winter MA; Hsaio SC; Pearce HL; Beck WT; Dantzig AH
Biochem Pharmacol; 1998 Sep; 56(6):719-27. PubMed ID: 9751076
[TBL] [Abstract][Full Text] [Related]
13. Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.
Ritchie TK; Kwon H; Atkins WM
J Biol Chem; 2011 Nov; 286(45):39489-96. PubMed ID: 21937435
[TBL] [Abstract][Full Text] [Related]
14. Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.
Mu XY; Gosland MP; Bartik MM; Schimmelpfennig J; Kay NE
J Clin Immunol; 1999 Jul; 19(4):239-46. PubMed ID: 10471978
[TBL] [Abstract][Full Text] [Related]
15. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.
Schinkel AH; Arceci RJ; Smit JJ; Wagenaar E; Baas F; Dollé M; Tsuruo T; Mechetner EB; Roninson IB; Borst P
Int J Cancer; 1993 Sep; 55(3):478-84. PubMed ID: 8104165
[TBL] [Abstract][Full Text] [Related]
16. Dissection of drug-binding-induced conformational changes in P-glycoprotein.
Wang G; Pincheira R; Zhang JT
Eur J Biochem; 1998 Jul; 255(2):383-90. PubMed ID: 9716379
[TBL] [Abstract][Full Text] [Related]
17. The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2.
Zhou Y; Gottesman MM; Pastan I
Arch Biochem Biophys; 1999 Jul; 367(1):74-80. PubMed ID: 10375401
[TBL] [Abstract][Full Text] [Related]
18. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
[TBL] [Abstract][Full Text] [Related]
19. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.
Park SW; Lomri N; Simeoni LA; Fruehauf JP; Mechetner E
Cytometry A; 2003 Jun; 53(2):67-78. PubMed ID: 12766968
[TBL] [Abstract][Full Text] [Related]
20. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
Wang L; Kitaichi K; Hui CS; Takagi K; Takagi K; Sakai M; Yokogawa K; Miyamoto KI; Hasegawa T
Clin Exp Pharmacol Physiol; 2000 Aug; 27(8):587-93. PubMed ID: 10901387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
